This invention relates to a crosslinking component for binder resins which is especially suitable to be used together with epoxy-group containing binders and/or (poly)isocyanates such as blocked (poly)isocyanates and which comprises at least two blocked isocyanate groups per molecule of the crosslinking component whereby at least one of the at least two blocked isocyanate groups is a group according to structural unit (I), wherein the ratio of structural units of formula (II), if present, to structural units of formula (I) is 0.40 or below. The cross-linking component may also be self-cross-linkable. The present invention further relates to a coating composition, e.g. a one-component coating composition comprising the crosslinking component and a method of its manufacture.

A method for producing an isocyanate, comprising: a carbamation step of generating an N-substituted carbamate from an organic primary amine, urea and an organic hydroxy compound according to a carbamation reaction, and then recovering a first gaseous phase component containing the urea and/or a compound having a carbonyl group derived from the urea, the organic hydroxy compound, and ammonia; a condensation step of condensing the first gaseous phase component with a condenser; an isocyanate production step of producing an isocyanate by subjecting the N-substituted carbamate to pyrolysis; an ammonia absorption step of allowing a second gaseous phase component containing ammonia recovered as a gaseous phase component from the condenser as a main component, to be absorbed by absorption water, and generating gas-absorbed water; and an ammonia stripping step of heating the gas-absorbed water to separate ammonia from the gas-absorbed water.

A method for producing an isocyanate, comprising: a carbamation step of generating an N-substituted carbamate from an organic primary amine, urea and an organic hydroxy compound according to a carbamation reaction, and then recovering a first gaseous phase component containing the urea and/or a compound having a carbonyl group derived from the urea, the organic hydroxy compound, and ammonia; a condensation step of condensing the first gaseous phase component with a condenser; an isocyanate production step of producing an isocyanate by subjecting the N-substituted carbamate to pyrolysis; an ammonia absorption step of allowing a second gaseous phase component containing ammonia recovered as a gaseous phase component from the condenser as a main component, to be absorbed by absorption water, and generating gas-absorbed water; and an ammonia stripping step of heating the gas-absorbed water to separate ammonia from the gas-absorbed water.

The invention relates to a compound comprising at least two (NHCO) groups and at least two (CO)CCR.sup.1 groups, wherein R.sup.1 represents hydrogen or a group having from 1 to 12 carbon atoms; a curable composition comprising a first unit comprising at least two (NHCO) groups, a second unit comprising at least two (CO)CCR.sup.1 groups, and a catalyst; and the use of the composition as an adhesive, coating, casting composition or as sealant.

The invention relates to a compound comprising at least two (NHCO) groups and at least two (CO)CCR.sup.1 groups, wherein R.sup.1 represents hydrogen or a group having from 1 to 12 carbon atoms; a curable composition comprising a first unit comprising at least two (NHCO) groups, a second unit comprising at least two (CO)CCR.sup.1 groups, and a catalyst; and the use of the composition as an adhesive, coating, casting composition or as sealant.

The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, ##STR00001##
comprising deprotecting a compound of formula II ##STR00002##
wherein each R.sup.3 independently represents a tertiary alkyl group, preferably wherein each R.sup.3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula I and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula I and their use in the treatment of proliferative disorders.

The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof, ##STR00001##
comprising deprotecting a compound of formula II ##STR00002##
wherein each R.sup.3 independently represents a tertiary alkyl group, preferably wherein each R.sup.3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula I and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula I and their use in the treatment of proliferative disorders.

Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (2) a prodrug using a linker such as an unsaturated carboxylic ester between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (3) esters of long-chain fatty acids and capsaicin where hydroxyl groups provide handles for attachment of additional capsaicin molecules; and (4) the use of carboxylic acid diesters to increase overall hydrophobicity of two or more covalently-linked capsaicin molecules. Formulations of palmitated esters of capsaicin are also described, which are designed to enhance hydrophobicity of a molecule useful for pharmaceutical applications, for example to provide compounded mixtures designed to optimize analgesic efficacy.

Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (2) a prodrug using a linker such as an unsaturated carboxylic ester between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (3) esters of long-chain fatty acids and capsaicin where hydroxyl groups provide handles for attachment of additional capsaicin molecules; and (4) the use of carboxylic acid diesters to increase overall hydrophobicity of two or more covalently-linked capsaicin molecules. Formulations of palmitated esters of capsaicin are also described, which are designed to enhance hydrophobicity of a molecule useful for pharmaceutical applications, for example to provide compounded mixtures designed to optimize analgesic efficacy.

The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to treat the associated diseases and conditions, such as heparin-induced thrombocytopenia and thrombosis (HITT) and vaccine-induced immune thrombotic thrombocytopenia (VITT), methods of making these compounds, and pharmaceutical compositions containing these compounds are also disclosed.

##STR00001##